Genetic subtypes of B-cell acute lymphoblastic leukemia in adults Available to Purchase

2.

Iacobucci

I

,

Mullighan

CG

.

Genetic basis of acute lymphoblastic leukemia

.

J Clin Oncol

.

2017

;

35

(

9

):

975

-

983

.

3.

Yeoh

E-J

,

Ross

ME

,

Shurtleff

SA

, et al.

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling

.

Cancer Cell

.

2002

;

1

(

2

):

133

-

143

.

4.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

5.

Foà

R

,

Bassan

R

,

Elia

L

, et al.

Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL

.

J Clin Oncol

.

2023

;

42

(

8

):

881

-

885

.

6.

Chalandon

Y

,

Rousselot

P

,

Chevret

S

, et al.

Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia

.

Blood

.

2024

;

143

(

23

):

2363

-

2372

.

7.

Kantarjian

H

,

Short

NJ

,

Haddad

FG

, et al.

Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL

.

J Clin Oncol

.

2024

;

42

(

36

):

4246

-

4251

.

8.

Jain

N

,

Roberts

KG

,

Jabbour

E

, et al.

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

.

Blood

.

2017

;

129

(

5

):

572

-

581

.

9.

Iacobucci

I

,

Roberts

KG

.

Genetic alterations and therapeutic targeting of Philadelphia-like acute lymphoblastic leukemia

.

Genes

.

2021

;

12

(

5

):

687

.

10.

Li

J-F

,

Dai

Y-T

,

Lilljebjörn

H

, et al.

Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases

.

Proc Natl Acad Sci U S A

.

2018

;

115

(

50

):

E11711

-

E11720

.

11.

Passet

M

,

Kim

R

,

Gachet

S

, et al.

Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

.

Blood

.

2022

;

139

(

24

):

3505

-

3518

.

12.

Kimura

S

,

Montefiori

L

,

Iacobucci

I

, et al.

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

.

Blood

.

2022

;

139

(

24

):

3519

-

3531

.

13.

Bastian

L

,

Hartmann

AM

,

Beder

T

, et al.

UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

.

Leukemia

.

2022

;

36

(

6

):

1676

-

1680

.

14.

Paietta

E

,

Roberts

KG

,

Wang

V

, et al.

Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL

.

Blood

.

2021

;

138

(

11

):

948

-

958

.

15.

Gu

Z

,

Churchman

ML

,

Roberts

KG

, et al.

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

.

Nat Genet

.

2019

;

51

(

2

):

296

-

307

.

16.

Burmeister

T

,

Gökbuget

N

,

Schwartz

S

, et al.

Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia

.

Haematologica

.

2010

;

95

(

2

):

241

-

246

.

17.

Lafage-Pochitaloff

M

,

Baranger

L

,

Hunault

M

, et al.

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia

.

Blood

.

2017

;

130

(

16

):

1832

-

1844

.

18.

Moorman

AV

,

Barretta

E

,

Butler

ER

, et al.

Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study

.

Leukemia

.

2022

;

36

(

3

):

625

-

636

.

19.

Harrison

CJ

,

Moorman

AV

,

Schwab

C

, et al.

An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome

.

Leukemia

.

2014

;

28

(

5

):

1015

-

1021

.

20.

Yasuda

T

,

Sanada

M

,

Kawazu

M

, et al.

Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations

.

Blood

.

2022

;

139

(

12

):

1850

-

1862

.

21.

Marks

DI

,

Moorman

AV

,

Chilton

L

, et al.

The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial

.

Haematologica

.

2013

;

98

(

6

):

945

-

952

.

22.

Richard-Carpentier

G

,

Kantarjian

HM

,

Tang

G

, et al.

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience

.

Blood Adv

.

2021

;

5

(

23

):

5415

-

5419

.

23.

Kim

R

,

Bergugnat

H

,

Pastoret

C

, et al.

Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study

.

Blood

.

2023

;

142

(

21

):

1806

-

1817

.

24.

Kim

R

,

Bergugnat

H

,

Larcher

L

, et al.

Adult low-hypodiploid acute lymphoblastic leukemia emerges from preleukemic TP53-mutant clonal hematopoiesis

.

Blood Cancer Discov

.

2023

;

4

(

2

):

134

-

149

.

25.

Holmfeldt

L

,

Wei

L

,

Diaz-Flores

E

, et al.

The genomic landscape of hypodiploid acute lymphoblastic leukemia

.

Nat Genet

.

2013

;

45

(

3

):

242

-

252

.

26.

Harrison

CJ

,

Moorman

AV

,

Broadfield

ZJ

, et al.

Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia

.

Br J Haematol

.

2004

;

125

(

5

):

552

-

559

.

27.

Gu

Z

,

Churchman

M

,

Roberts

K

, et al.

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

.

Nat Commun

.

2016

;

7

:

13331

.

28.

Bomken

S

,

Enshaei

A

,

Schwalbe

EC

, et al.

Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement

.

Haematologica

.

2023

;

108

(

3

):

717

-

731

.

29.

Pui

CH

,

Carroll

AJ

,

Raimondi

SC

, et al.

Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line

.

Blood

.

1990

;

75

(

5

):

1170

-

1177

.

30.

Boer

JM

,

Valsecchi

MG

,

Hormann

FM

, et al.

Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study

.

Leukemia

.

2021

;

35

(

10

):

2978

-

2982

.

31.

Passet

M

,

Boissel

N

,

Sigaux

F

, et al.

PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome

.

Blood

.

2019

;

133

(

3

):

280

-

284

.

32.

Bastian

L

,

Schroeder

MP

,

Eckert

C

, et al.

PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia

.

Leukemia

.

2019

;

33

(

8

):

1895

-

1909

.

33.

Yilmaz

M

,

Kantarjian

HM

,

Toruner

G

, et al.

Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosis

.

Leuk Lymphoma

.

2021

;

62

(

1

):

224

-

228

.

34.

Fischer

U

,

Forster

M

,

Rinaldi

A

, et al.

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options

.

Nat Genet

.

2015

;

47

(

9

):

1020

-

1029

.

35.

Hirabayashi

S

,

Ohki

K

,

Nakabayashi

K

, et al.

ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype

.

Haematologica

.

2017

;

102

(

1

):

118

-

129

.

36.

Qin

Y-Z

,

Jiang

Q

,

Xu

L-P

, et al.

The prognostic significance of ZNF384 fusions in adult Ph-negative B-cell precursor acute lymphoblastic leukemia: a comprehensive cohort study from a single Chinese center.

.

Front Oncol

.

2021

;

11

:

632532

.

37.

Chiaretti

S

,

Foà

R

.

How I treat adult Ph+ ALL

.

Blood

.

2025

;

145

(

1

):

11

-

19

.

38.

Brady

SW

,

Roberts

KG

,

Gu

Z

, et al.

The genomic landscape of pediatric acute lymphoblastic leukemia

.

Nat Genet

.

2022

;

54

(

9

):

1376

-

1389

.

39.

Pfeifer

H

,

Raum

K

,

Markovic

S

, et al.

Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation

.

Blood

.

2018

;

131

(

13

):

1464

-

1475

.

40.

Fedullo

AL

,

Messina

M

,

Elia

L

, et al.

Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia

.

Haematologica

.

2019

;

104

(

2

):

312

-

318

.

41.

Hovorkova

L

,

Zaliova

M

,

Venn

NC

, et al.

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

.

Blood

.

2017

;

129

(

20

):

2771

-

2781

.

42.

Short

NJ

,

Jabbour

E

,

Macaron

W

, et al.

Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1

.

Am J Hematol

.

2023

;

98

(

8

):

1196

-

1203

.

43.

Zuna

J

,

Hovorkova

L

,

Krotka

J

, et al.

Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease

.

Leukemia

.

2022

;

36

(

12

):

2793

-

2801

.

44.

Kim

R

,

Chalandon

Y

,

Rousselot

P

, et al.

Significance of measurable residual disease in adult Philadelphia chromosome-positive ALL: a GRAAPH-2014 study

.

J Clin Oncol

.

2024

;

42

(

26

):

3140

-

3150

.

45.

Kim

JC

,

Chan-Seng-Yue

M

,

Ge

S

, et al.

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia

.

Nat Genet

.

2023

;

55

(

7

):

1186

-

1197

.

46.

Bastian

L

,

Beder

T

,

Barz

MJ

, et al.

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL

.

Blood

.

2024

;

143

(

14

):

1391

-

1398

.

47.

Zuna

J

,

Hovorkova

L

,

Krotka

J

, et al.

Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: should we keep track?

.

Am J Hematol

.

2023

;

98

(

10

):

E269

-

E271

.

48.

Creasey

T

,

Barretta

E

,

Ryan

SL

, et al.

Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials

.

Haematologica

.

2022

;

107

(

9

):

2051

-

2063

.

49.

Chitadze

G

,

Stengel

A

,

John-Klaua

C

, et al.

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia

.

Blood

.

2023

;

141

(

13

):

1640

-

1644

.

50.

Saygin

C

,

Zhang

P

,

Stauber

J

, et al.

Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis

.

Blood Cancer Discov

.

2024

;

5

(

3

):

164

-

179

.

51.

Barnea Slonim

L

,

Gao

J

,

Burkart

M

, et al.

Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome

.

Leukemia

.

2021

;

35

(

7

):

2097

-

2101

.

52.

Parrondo

RD

,

Rahman

ZA

,

Heckman

MG

, et al.

Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma

.

Blood Cancer J

.

2022

;

12

(

6

):

87

.

53.

Geyer

MB

,

Shaffer

BC

,

Bhatnagar

B

, et al.

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal

.

Blood Adv

.

2023

;

7

(

13

):

3087

-

3098

.

54.

Meyer

C

,

Larghero

P

,

Almeida Lopes

B

, et al.

The KMT2A recombinome of acute leukemias in 2023

.

Leukemia

.

2023

;

37

(

5

):

988

-

1005

.

55.

Aldoss

I

,

Stiller

T

,

Tsai

N-C

, et al.

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients

.

Haematologica

.

2018

;

103

(

10

):

1662

-

1668

.

56.

Saygin

C

,

Kishtagari

A

,

Cassaday

RD

, et al.

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

.

Blood Adv

.

2019

;

3

(

24

):

4228

-

4237

.

57.

Pourhassan

H

,

Zhang

J

,

Tinajero

J

, et al.

Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer

.

Br J Haematol

.

2024

;

205

(

1

):

158

-

165

.

58.

Ribera

J-M

.

Therapy-related acute lymphoblastic leukemia

.

Haematologica

.

2018

;

103

(

10

):

1581

-

1583

.

59.

Kamens

JL

,

Nance

S

,

Koss

C

, et al.

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia

.

Nat Commun

.

2023

;

14

(

1

):

809

.

60.

Tejedor

JR

,

Bueno

C

,

Vinyoles

M

, et al.

Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia

.

J Clin Invest

.

2021

;

131

(

13

):

e138833

.

61.

Agraz-Doblas

A

,

Bueno

C

,

Bashford-Rogers

R

, et al.

Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis

.

Haematologica

.

2019

;

104

(

6

):

1176

-

1188

.

62.

Krivtsov

AV

,

Evans

K

,

Gadrey

JY

, et al.

A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia

.

Cancer Cell

.

2019

;

36

(

6

):

660

-

673.e11

.

63.

Issa

GC

,

Aldoss

I

,

DiPersio

J

, et al.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

.

Nature

.

2023

;

615

(

7954

):

920

-

924

.

64.

Woodward

EL

,

Yang

M

,

Moura-Castro

LH

, et al.

Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia

.

Nat Commun

.

2023

;

14

(

1

):

1658

.

65.

Ribera

J

,

Granada

I

,

Morgades

M

, et al.

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols

.

Br J Haematol

.

2022

;

196

(

3

):

670

-

675

.

66.

Mouttet

B

,

Vinti

L

,

Ancliff

P

, et al.

Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation

.

Haematologica

.

2019

;

104

(

6

):

e244

-

e247

.

67.

Huang

Y

,

Mouttet

B

,

Warnatz

H-J

, et al.

The Leukemogenic TCF3-HLF complex rewires enhancers driving cellular identity and self-renewal conferring EP300 vulnerability

.

Cancer Cell

.

2019

;

36

(

6

):

630

-

644.e9

.

68.

Gao

Q

,

Ryan

SL

,

Iacobucci

I

, et al.

The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21

.

Blood

.

2023

;

142

(

8

):

711

-

723

.

69.

Den Boer

ML

,

van Slegtenhorst

M

,

De Menezes

RX

, et al.

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

.

Lancet Oncol

.

2009

;

10

(

2

):

125

-

134

.

70.

Harvey

RC

,

Mullighan

CG

,

Wang

X

, et al.

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome

.

Blood

.

2010

;

116

(

23

):

4874

-

4884

.

71.

Roberts

KG

,

Li

Y

,

Payne-Turner

D

, et al.

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

.

N Engl J Med

.

2014

;

371

(

11

):

1005

-

1015

.

72.

Roberts

KG

,

Gu

Z

,

Payne-Turner

D

, et al.

High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults

.

J Clin Oncol

.

2017

;

35

(

4

):

394

-

401

.

73.

Tanasi

I

,

Ba

I

,

Sirvent

N

, et al.

Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements

.

Blood

.

2019

;

134

(

16

):

1351

-

1355

.

74.

Cario

G

,

Leoni

V

,

Conter

V

, et al.

Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols

.

Haematologica

.

2020

;

105

(

7

):

1887

-

1894

.

75.

van Outersterp

I

,

Tasian

SK

,

Reichert

CE

, et al.

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain

.

Blood

.

2024

;

143

(

21

):

2178

-

2189

.

76.

Russell

LJ

,

Capasso

M

,

Vater

I

, et al.

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia

.

Blood

.

2009

;

114

(

13

):

2688

-

2698

.

77.

Mullighan

CG

,

Collins-Underwood

JR

,

Phillips

LAA

, et al.

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia

.

Nat Genet

.

2009

;

41

(

11

):

1243

-

1246

.

78.

Herold

T

,

Schneider

S

,

Metzeler

KH

, et al.

Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis

.

Haematologica

.

2017

;

102

(

1

):

130

-

138

.

79.

Iacobucci

I

,

Li

Y

,

Roberts

KG

, et al.

Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia

.

Cancer Cell

.

2016

;

29

(

2

):

186

-

200

.

80.

Pui

C-H

,

Roberts

KG

,

Yang

JJ

,

Mullighan

CG

.

Philadelphia chromosome-like acute lymphoblastic leukemia

.

Clin Lymphoma Myeloma Leuk

.

2017

;

17

(

8

):

464

-

470

.

81.

Chiaretti

S

,

Messina

M

,

Foà

R

.

BCR/ABL1-like acute lymphoblastic leukemia: how to diagnose and treat?

.

Cancer

.

2019

;

125

(

2

):

194

-

204

.

82.

Tran

TH

,

Tasian

SK

.

How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults

.

Blood

.

2024

;

145

(

1

):

20

-

34

.

83.

Zaliova

M

,

Winkowska

L

,

Stuchly

J

, et al.

A novel class of ZNF384 aberrations in acute leukemia

.

Blood Adv

.

2021

;

5

(

21

):

4393

-

4397

.

84.

Alexander

TB

,

Gu

Z

,

Iacobucci

I

, et al.

The genetic basis and cell of origin of mixed phenotype acute leukaemia

.

Nature

.

2018

;

562

(

7727

):

373

-

379

.

85.

Chiaretti

S

,

Taherinasab

A

,

Della Starza

I

, et al.

ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings

.

Leuk Lymphoma

.

2023

;

64

(

2

):

483

-

486

.

86.

Novakova

M

,

Zaliova

M

,

Fiser

K

, et al.

DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch

.

Haematologica

.

2021

;

106

(

8

):

2066

-

2075

.

87.

Griffith

M

,

Griffith

OL

,

Krysiak

K

, et al.

Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia

.

Exp Hematol

.

2016

;

44

(

7

):

603

-

613

.

88.

Zhao

X

,

Wang

P

,

Diedrich

JD

, et al.

Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia

.

Nat Commun

.

2022

;

13

(

1

):

5401

.

89.

Clappier

E

,

Auclerc

MF

,

Rapion

J

, et al.

An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions

.

Leukemia

.

2014

;

28

(

1

):

70

-

77

.

90.

Zaliova

M

,

Zimmermannova

O

,

Dörge

P

, et al.

ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia

.

Leukemia

.

2014

;

28

(

1

):

182

-

185

.

91.

Yasuda

T

,

Tsuzuki

S

,

Kawazu

M

, et al.

Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults

.

Nat Genet

.

2016

;

48

(

5

):

569

-

574

.

92.

Lilljebjörn

H

,

Henningsson

R

,

Hyrenius-Wittsten

A

, et al.

Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia

.

Nat Commun

.

2016

;

7

:

11790

.

93.

Zhang

J

,

McCastlain

K

,

Yoshihara

H

, et al.

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia

.

Nat Genet

.

2016

;

48

(

12

):

1481

-

1489

.

94.

Schinnerl

D

,

Mejstrikova

E

,

Schumich

A

, et al.

CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia

.

Haematologica

.

2019

;

104

(

8

):

e352

-

e355

.

95.

Buldini

B

,

Varotto

E

,

Maurer-Granofszky

M

, et al.

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

.

Blood

.

2024

;

143

(

17

):

1738

-

1751

.

96.

Thorsson

H

,

Henningsson

R

,

Puente-Moncada

N

, et al.

Single-cell genomics details the maturation block in BCP-ALL and identifies therapeutic vulnerabilities in DUX4-r cases

.

Blood

.

2024

;

44

(

13

):

1399

-

1411

.

97.

Strehl

S

,

König

M

,

Dworzak

MN

,

Kalwak

K

,

Haas

OA

.

PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13)

.

Leukemia

.

2003

;

17

(

6

):

1121

-

1123

.

98.

Bousquet

M

,

Broccardo

C

,

Quelen

C

, et al.

A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5

.

Blood

.

2007

;

109

(

8

):

3417

-

3423

.

99.

Coyaud

E

,

Struski

S

,

Prade

N

, et al.

Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study

.

Blood

.

2010

;

115

(

15

):

3089

-

3097

.

100.

Fazio

G

,

Daniele

G

,

Cazzaniga

V

, et al.

Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia

.

Haematologica

.

2015

;

100

(

1

):

e14

-

e17

.

101.

Rutherford

SC

,

Abramson

JS

,

Bartlett

NL

, et al.

Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study

.

Lancet Haematol

.

2021

;

8

(

11

):

e818

-

e827

.

102.

Lilljebjörn

H

,

Ågerstam

H

,

Orsmark-Pietras

C

, et al.

RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib

.

Leukemia

.

2014

;

28

(

4

):

977

-

979

.

103.

Ohki

K

,

Kiyokawa

N

,

Saito

Y

, et al.

Clinical and molecular characteristics of MEF2D fusion-positive precursor B-cell acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion

.

Haematologica

.

2019

;

104

(

1

):

128

-

137

.

104.

Ohki

K

,

Butler

ER

,

Kiyokawa

N

, et al.

Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

.

Leukemia

.

2023

;

37

(

1

):

212

-

216

.

105.

Akasaka

T

,

Balasas

T

,

Russell

LJ

, et al.

Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

.

Blood

.

2007

;

109

(

8

):

3451

-

3461

.

106.

Chapiro

E

,

Radford-Weiss

I

,

Cung

H-A

, et al.

Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature

.

Cancer Genet

.

2013

;

206

(

5

):

162

-

173

.

107.

Russell

LJ

,

Enshaei

A

,

Jones

L

, et al.

IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome

.

J Clin Oncol

.

2014

;

32

(

14

):

1453

-

1462

.

108.

Zaliova

M

,

Potuckova

E

,

Lukes

J

, et al.

Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia

.

Haematologica

.

2021

;

106

(

3

):

886

-

890

.

109.

Li

Z

,

Chang

T-C

,

Junco

JJ

, et al.

Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia

.

Blood

.

2023

;

142

(

2

):

172

-

184

.

110.

Hormann

FM

,

Hoogkamer

AQ

,

Beverloo

HB

, et al.

NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2

.

Haematologica

.

2019

;

104

(

10

):

e455

-

e459

.

111.

Beldjord

K

,

Chevret

S

,

Asnafi

V

, et al.

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

.

Blood

.

2014

;

123

(

24

):

3739

-

3749

.

112.

Mitchell

RJ

,

Kirkwood

AA

,

Barretta

E

, et al.

IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial

.

Blood Adv

.

2021

;

5

(

17

):

3322

-

3332

.

113.

Kimura

H

,

Onozawa

M

,

Yoshida

S

, et al.

Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia

.

Ann Hematol

.

2023

;

102

(

11

):

3103

-

3113

.

114.

Smith

AC

,

Neveling

K

,

Kanagal-Shamanna

R

.

Optical genome mapping for structural variation analysis in hematologic malignancies

.

Am J Hematol

.

2022

;

97

(

7

):

975

-

982

.

115.

Leongamornlert

D

,

Gutiérrez-Abril

J

,

Lee

S

, et al.

Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia

.

Blood Adv

.

2023

;

7

(

15

):

3862

-

3873

.

116.

Beder

T

,

Hansen

B-T

,

Hartmann

AM

, et al.

The gene expression classifier ALLCatchR identifies B-cell precursor ALL subtypes and underlying developmental trajectories across age

.

Hemasphere

.

2023

;

7

(

9

):

e939

.

117.

Hu

Z

,

Jia

Z

,

Liu

J

,

Mao

A

,

Han

H

,

Gu

Z

.

MD-ALL: an integrative platform for molecular diagnosis of B-acute lymphoblastic leukemia

.

Haematologica

.

2024

;

109

(

6

):

1741

-

1754

.

118.

Caye

A

,

Beldjord

K

,

Mass-Malo

K

, et al.

Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia

.

Haematologica

.

2013

;

98

(

4

):

597

-

601

.

119.

Darzentas

F

,

Szczepanowski

M

,

Kotrová

M

, et al.

Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications

.

Front Immunol

.

2023

;

14

:

1125017

.

120.

Darzentas

F

,

Szczepanowski

M

,

Kotrová

M

, et al.

IGH rearrangement evolution in adult KMT2A-rearranged B-cell precursor ALL: implications for cell-of-origin and MRD monitoring

.

Hemasphere

.

2023

;

7

(

1

):

e820

.

121.

Tirtakusuma

R

,

Szoltysek

K

,

Milne

P

, et al.

Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia

.

Blood

.

2022

;

140

(

17

):

1875

-

1890

.

122.

Semchenkova

A

,

Mikhailova

E

,

Komkov

A

, et al.

Lineage conversion in pediatric B-cell precursor acute leukemia under blinatumomab therapy

.

Int J Mol Sci

.

2022

;

23

(

7

):

4019

.

123.

Bełdzińska-Gądek

K

,

Zarzycka

E

,

Pastuszak

K

, et al.

Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia

.

Leuk Lymphoma

.

2024

;

65

(

9

):

1292

-

1302

.

124.

Chen

X

,

Gao

Q

,

Roshal

M

,

Cherian

S

.

Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy

.

Cytometry B Clin Cytom

.

2023

;

104

(

3

):

205

-

223

.

125.

Zhao

Y

,

Laird

AD

,

Roberts

KG

, et al.

Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL

.

Blood Adv

.

2024

;

8

(

12

):

3226

-

3236

.

126.

Zhao

Y

,

Aldoss

I

,

Qu

C

, et al.

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL

.

Blood

.

2021

;

137

(

4

):

471

-

484

.

127.

Gardner

R

,

Wu

D

,

Cherian

S

, et al.

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

.

Blood

.

2016

;

127

(

20

):

2406

-

2410

.

128.

Orlando

EJ

,

Han

X

,

Tribouley

C

, et al.

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

.

Nat Med

.

2018

;

24

(

10

):

1504

-

1506

.

129.

Zhao

Y

,

Short

NJ

,

Kantarjian

HM

, et al.

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

.

Blood

.

2024

;

144

(

1

):

61

-

73

.

130.

Oberley

MJ

,

Gaynon

PS

,

Bhojwani

D

, et al.

Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia

.

Pediatr Blood Cancer

.

2018

;

65

(

9

):

e27265

.

131.

Li

Y

,

Moriyama

T

,

Yoshimura

S

, et al.

PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia

.

Sci Adv

.

2022

;

8

(

50

):

eadd6403

.

132.

Shah

NN

,

Stevenson

MS

,

Yuan

CM

, et al.

Characterization of CD22 expression in acute lymphoblastic leukemia

.

Pediatr Blood Cancer

.

2015

;

62

(

6

):

964

-

969

.

133.

Kantarjian

HM

,

DeAngelo

DJ

,

Stelljes

M

, et al.

Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia

.

N Engl J Med

.

2016

;

375

(

8

):

740

-

753

.

134.

Kantarjian

HM

,

Stock

W

,

Cassaday

RD

, et al.

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and bafety by baseline CD22

.

Clin Cancer Res

.

2021

;

27

(

10

):

2742

-

2754

.

135.

O’Brien

MM

,

Ji

L

,

Shah

NN

, et al.

Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children’s Oncology Group protocol AALL1621

.

J Clin Oncol

.

2022

;

40

(

9

):

956

-

967

.

136.

Yoshimura

S

,

Li

Z

,

Gocho

Y

, et al.

Impact of age on pharmacogenomics and treatment outcomes of B-cell acute lymphoblastic leukemia

.

J Clin Oncol

.

2024

;

42

(

29

):

3478

-

3490

.